Addressing the Challenges of Novel Oncology and Hematology Treatments Across Sites of Care: Specialty Pharmacy Solutions

1. Dusetzina, S, Haiden, H, Keating, N. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in medicare part D, 2010 to 2019. JAMA 2019; 321: 2025–2028.
Google Scholar | Crossref | Medline2. Zuckerman, A, Carver, A, Cooper, K, et al. An integrated health-system specialty pharmacy model for coordinating transitions of care: specialty medication challenges and specialty pharmacist opportunities. MDPI 2019; 7: 163.
Google Scholar3. Streeter, SB, Schwartzberg, L, Husain, N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011; 7: 46s–51s.
Google Scholar | Crossref | Medline4. Wyatt, H, Peter, M, Zuckerman, A, et al. Assessing the impact of limited distribution drug networks based on time to accessing oral oncolytic agents at an integrated specialty pharmacy. J Hematol Oncol Pharm 2020; 10: 198–205.
Google Scholar5. Zuckerman, A, Douglas, A, Nwosu, S, et al. Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era. PLoS ONE 2018; 13: e0199174.
Google Scholar | Medline6. Reynolds, V, Chinn, M, Jolly, J, et al. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates. J Clin Lipid 2019; 13: 254–264.
Google Scholar | Crossref | Medline7. Cocohoba, J, Pohlman, B, Sang Tran, J, et al. Modeling specialty medicine access: understanding key health system processes and players. JAPhA 2019; 59: 43–50.
Google Scholar8. Fajardo, S, Zook, F, Dotson, E. Specialty pharmacy for hematologic malignancies. Am J Health-System Pharm 2016; 73: 797–809.
Google Scholar | Crossref | Medline9. Bagwell, A, Kelley, T, Carver, A, et al. Advancing patient care through specialty pharmacy services in an academic health system. J Manag Care Spec Pharm 2017; 23: 815–820.
Google Scholar | Medline10. Drenker, K, Sondag, A, Mancini, R. Impact of a pharmacist-managed oral chemotherapy program on nonfulfillment rates. J Hematol Oncol Pharm 2012; 2: 42–45.
Google Scholar11. Khorana, AA, Tullio, K, Pennell, NA, et al. Time to initial cancer treatment in the United States and association with survival over time: an observational study. PLoS ONE 2019; 14: e0215108.
Google Scholar | Medline12. Mancini, R, Kaster, L, Vu, B, et al. Implementation of a pharmacist-managed interdisciplinary oral chemotherapy program in a community cancer center. J Hematol Oncol Pharm 2011; 1: 23–30.
Google Scholar13. Bertsch, N, Bindler, R, Wilson, P, et al. Medication therapy management for patients receiving oral chemotherapy agents at a community oncology center: a pilot study. Hosp Pharm 2016; 51: 721–729.
Google Scholar | SAGE Journals14. Morgan, K, Muluneh, B, Deal, A, et al. Impact of an integrated oral chemotherapy program on patient adherence. J Oncol Pharm Pract 2018; 24: 332–336.
Google Scholar | SAGE Journals | ISI15. Stubbings, J , et al. ASHP National survey of health-system specialty pharmacy practice—2020. Am J Health-Syst Pharm 2021; 78: 1765–1791.
Google Scholar | Crossref | Medline16. Vogenberg, F, Gomes, J. The changing roles of P&T committees: a look back at the last decade and a look forward to 2022. P&T. 2014 2014; 39: 760–772.
Google Scholar17. Dasatinib . Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc., 2021 [updated 6 June 2021; cited 25 June 2021]. Available from: http://online.lexi.com. Subscription required to view.
Google Scholar18. Caplacizumab . Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc., 2021 [updated 24 Mar 2021; cited 25 June 2021]. Available from: http://online.lexi.com (accessed 25 June 2021). Subscription required to view.
Google Scholar19. Cablivi (caplacizumab) [package insert]. Cambridge, MA: Genzyme Corporation; 2019.
Google Scholar20. Holle, L, Michaud, B. Oncology pharmacists in health care delivery: vital members of the cancer care team. J Clin Onc 2014; 10: 142–145.
Google Scholar21. Tschida, S, Aslam, S, Lal, L, et al. Outcomes of a specialty pharmacy program for oral oncology medications. Am J Pharm Benef 2012; 4: 165-174.
Google Scholar

留言 (0)

沒有登入
gif